Praxis Precision Medicines, Inc. revealed a surprising Phase II/III failure for major depression disorder (MDD) candidate PRAX-114 but was praised by analysts for moving quickly to re-center its R&D efforts on mid-stage essential tremor and epilepsy programs.
The company announced on 6 June that its GABA-alpha positive allosteric modulator failed to meet the primary endpoint and also...